CoChat

Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy

Open access

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

The success of chemotherapy largely depends on the anticancer immune response triggered by tumor cells that succumb to immunogenic cell death (ICD). One of the hallmarks of ICD is premortem autophagy that facilitates the release of adenosine triphosphate from dying cancer cells and acts as a chemoattractant for dendritic cell precursors. Here, we show that the immune response induced by inoculation of cancer cells undergoing ICD in response to the anthracycline mitoxantrone (MTX) can be improved by a short-term fasting regimen (48 hours of starvation) and that this effect is reversed by systemic administration of the autophagy inhibitor dimethyl α-ketoglutarate. Tumor growth reduction by MTX treatment is known to depend on autophagy induction in cancer cells as well as on an intact immune system. We compared the antitumor effects of MTX on autophagy-competent cancers implanted in wild type (WT) or partially autophagy-deficient (Becn1± or Atg4b−/-) mice. While there was no difference in the tumor growth reducing effects of MTX on tumors evolving in WT, Becn1+/- and Atg4b−/- mice, we observed an increase in the toxicity of MTX on Atg4b−/- mice. These results suggest that autophagy in cancer cells (but less so in host cells) is rate-limiting for therapeutically relevant anticancer immune responses, yet has a major role in blunting the life-threatening toxicity of chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2018.1498285

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Nutrient deprivation improves tumor vaccination efficacy in an autophagy dependent manner. (A). Schematic outline of the tumor vaccination experiment used in this study. MCA205 fibrosarcoma cells, cultured for 16 hours with mitoxantrone (MTX) to trigger immunogenic cell death, were inoculated into the left flank of 6 weeks-old female C57Bl6/mice. After injection, mice were starved for 48 hours and left untreated or administered (intraperitoneally, i.p.) with the autophagy inhibitor dimethyl-2-oxoglutarate (DMKG). At day 7, mice were rechallenged by injection of live MCA205 cells in the right flank and tumor appearance was monitored over time. (B). Representative analysis of the experiment depicted in (A). Data represent the pool of two different experiments. Statistical significance was calculated by means of the likelihood ratio test. * p < 0.05; *** p < 0.001.
Figure 1. Nutrient deprivation improves tumor vaccination efficacy in an autophagy dependent manner. (A). Schematic outline of the tumor vaccination experiment used in this study. MCA205 fibrosarcoma cells, cultured for 16 hours with mitoxantrone (MTX) to trigger immunogenic cell death, were inoculated into the left flank of 6 weeks-old female C57Bl6/mice. After injection, mice were starved for 48 hours and left untreated or administered (intraperitoneally, i.p.) with the autophagy inhibitor dimethyl-2-oxoglutarate (DMKG). At day 7, mice were rechallenged by injection of live MCA205 cells in the right flank and tumor appearance was monitored over time. (B). Representative analysis of the experiment depicted in (A). Data represent the pool of two different experiments. Statistical significance was calculated by means of the likelihood ratio test. * p < 0.05; *** p < 0.001.CC BY-NC-ND · PubMed Central
Figure 2. Systemic autophagy deficiency does not impact on the efficacy of anthracycline-based immunogenic chemotherapy. (A-C) Wild type (WT) autophagy competent C57BL/6 mice (A) or autophagy deficient Atg4b−/- (B) and Becn1+/- (C) mice were inoculated subcutaneously (s.c.) with murine fibrosarcoma MCA205 cells. When tumors reached a size of 25 mm2, mice received a single injection (i.p) of mitoxantrone (MTX) or an equivalent volume of PBS and tumor growth was routinely assessed. From left to right: average (± S.E.M) tumor growth curves of treated with PBS or MTX-based chemotherapy; tumor size distribution at day 26 of data; individual growth curves from mice treated with MTX or PBS. Data represent a pool of three different experiments. Statistical analysis of tumor growth curves was performed by Wald test whereas tumor size distribution at defined time points was analyzed by means of an unpaired t test. ** p < 0.01; *** p < 0.001.
Figure 2. Systemic autophagy deficiency does not impact on the efficacy of anthracycline-based immunogenic chemotherapy. (A-C) Wild type (WT) autophagy competent C57BL/6 mice (A) or autophagy deficient Atg4b−/- (B) and Becn1+/- (C) mice were inoculated subcutaneously (s.c.) with murine fibrosarcoma MCA205 cells. When tumors reached a size of 25 mm2, mice received a single injection (i.p) of mitoxantrone (MTX) or an equivalent volume of PBS and tumor growth was routinely assessed. From left to right: average (± S.E.M) tumor growth curves of treated with PBS or MTX-based chemotherapy; tumor size distribution at day 26 of data; individual growth curves from mice treated with MTX or PBS. Data represent a pool of three different experiments. Statistical analysis of tumor growth curves was performed by Wald test whereas tumor size distribution at defined time points was analyzed by means of an unpaired t test. ** p < 0.01; *** p < 0.001.CC BY-NC-ND · PubMed Central
Figure 3. Autophagy deficient mice show increased toxicity in response to anthracyclines based chemotherapy. (A-C) Wild type (WT) autophagy competent C57BL/6 mice (A) or autophagy deficient Atg4b−/- (B) and Becn1+/- (C) mice bearing MCA205 fibrosarcoma tumors received a single injection (i.p.) of mitoxantrone (MTX) or an equivalent volume of PBS, and bodyweight was monitored over time as an indicator of chemotherapy derived toxicity. Average (± S.E.M) (left panel) and individual (right panel) bodyweight curves are shown. Data represent a pool of three different experiments. Statistical analysis of body weight curves was performed by means of linear mixed-effect modeling (over the whole time course). (D) Comparison of MTX effects on body weight between autophagy competent WT and autophagy deficient mice. * p < 0.05 (for MTX WT vs MTX Atg4b−/- comparison); ## p < 0.01 (for MTX Atg4b−/- vs MTX Becn1+/- comparison). (E) Analysis of death type from autophagy competent versus autophagy deficient mice challenged with MTX chemotherapy. ns, non significant; *** p < 0.001 (binomial test). (F) Survival curves of MCA205 tumor bearing WT, Atg4b−/- and Becn1+/- mice. Statistical significance was assessed by means of log rank test. ** p < 0.01.
Figure 3. Autophagy deficient mice show increased toxicity in response to anthracyclines based chemotherapy. (A-C) Wild type (WT) autophagy competent C57BL/6 mice (A) or autophagy deficient Atg4b−/- (B) and Becn1+/- (C) mice bearing MCA205 fibrosarcoma tumors received a single injection (i.p.) of mitoxantrone (MTX) or an equivalent volume of PBS, and bodyweight was monitored over time as an indicator of chemotherapy derived toxicity. Average (± S.E.M) (left panel) and individual (right panel) bodyweight curves are shown. Data represent a pool of three different experiments. Statistical analysis of body weight curves was performed by means of linear mixed-effect modeling (over the whole time course). (D) Comparison of MTX effects on body weight between autophagy competent WT and autophagy deficient mice. * p < 0.05 (for MTX WT vs MTX Atg4b−/- comparison); ## p < 0.01 (for MTX Atg4b−/- vs MTX Becn1+/- comparison). (E) Analysis of death type from autophagy competent versus autophagy deficient mice challenged with MTX chemotherapy. ns, non significant; *** p < 0.001 (binomial test). (F) Survival curves of MCA205 tumor bearing WT, Atg4b−/- and Becn1+/- mice. Statistical significance was assessed by means of log rank test. ** p < 0.01.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Autophagy in the Pathogenesis of Disease

    Levine, B., & Kroemer, G. (2008) · Cell · doi:10.1016/j.cell.2007.12.018 · Cited by 7,069 · cited 1×

    “Major interventions on whole body physiology such as starvation or chemotherapy may impact on the autophagy system that – in teleological terms – aims at increasing the resilience of the organism against metabolic and toxic challenges.(30) In the context of cancer, autophagy induction may have oncopreventive and impro…”
    BackgroundSelf-citation
  • Immunogenic cell death in cancer and infectious disease

    Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119

    Self-citation
  • The role of autophagy during the early neonatal starvation period

    Kuma, A., Hatano, M., Matsui, M., Yamamoto, A., Nakaya, H., Yoshimori, T., Ohsumi, Y., Tokuhisa, T., & Mizushima, N. (2004) · Nature · doi:10.1038/nature03029 · Cited by 2,865 · cited 1×

    “Starvation of mice for 48h causes a ~ 20% weight loss associated with a massive autophagic response in multiple distinct nucleated cell types.(16,23) We tested the effect of fasting on the capacity of mice to mount a protective immune response against cancer cells succumbing to ICD induced by mitoxantrone (MTX) in vit…”
    Background
  • The immune contexture in cancer prognosis and treatment

    Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263

    Self-citation
  • Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

    Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512 · cited 1×

    “In mouse models, tumor growth reduction by chemotherapeutic agents often is dependent on T lymphocytes, meaning that tumors evolving in mice that lack T cells do not decrease their progression upon injection of cytotoxicants.(1,2) One efficient way to stimulate such therapeutically relevant antitumor immune responses…”
    BackgroundSelf-citation
  • Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice

    Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377 · cited 4×

    “This latter phenomenon is linked to autophagy, which is required for optimal release of ATP from dying cancer cells.(3) For this reason, autophagy-deficient cancer cells fail to release ATP in response to chemotherapy and thus are unable to recruit DCs into the tumor bed and to elicit an anti-tumor immune response.”
    BackgroundInfluentialSelf-citation
  • Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles

    Galluzzi, L., Bravo-San Pedro, J. M., Levine, B., Green, D. R., & Kroemer, G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.22 · Cited by 842 · cited 1×

    “Apparently such partial autophagy defects do not cause a major immunosuppressive effect, supporting the idea that autophagy in the tumor cells (rather than autophagy in immune effectors) is relevant to the therapeutic outcome of immunogenic chemotherapy.(36,37) As a caveat, we must insist on the fact that the systemic…”
    BackgroundSelf-citation
  • Fasting Cycles Retard Growth of Tumors and Sensitize a Range of Cancer Cell Types to Chemotherapy

    Lee, C., Raffaghello, L., Brandhorst, S., Safdie, F. M., Bianchi, G., Martin-Montalvo, A., Pistoia, V., Wei, M., Hwang, S., Merlino, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003293 · Cited by 715 · cited 1×

    “In addition, starvation, which is one of the best-known inducers of autophagy, increases the resistance of mice against the toxic effects of anthracyclinebased chemotherapy at the same time that it improves tumor growth reduction.(20,34) This autophagy- or starvationmediated improvement of chemotherapeutic responses h…”
    Background
  • Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells

    Ma, Y., Adjemian, S., Mattarollo, S. R., Yamazaki, T., Aymeric, L., Yang, H., Portela Catani, J. P., Hannani, D., Duret, H., Steegh, K., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.03.003 · Cited by 699 · cited 1×

    “ATP is normally confined to the intracellular space, yet can be released from stressed and dying cells into the extracellular compartment where it interacts with purinergic receptors, in particular P2Y2 purinergic receptors to attract myeloid cells including dendritic cell (DC) precursors into the tumor bed.(13,14) Th…”
    BackgroundSelf-citation
  • Autophagy and autophagy-related proteins in the immune system

    Shibutani, S. T., Saitoh, T., Nowag, H., Münz, C., & Yoshimori, T. (2015) · Nature Immunology · doi:10.1038/ni.3273 · Cited by 582 · cited 1×

    “Indeed, knockout of non-redundant autophagy genes (such as Atg5 or Atg7) in the hematopoietic lineage (or more specifically in myeloid or lymphoid subsets) has a strong immunosuppressive effect due to the loss of stem cell functions and an irreversible loss of cellular fitness precluding in-depth analyses of such phen…”
    Background

Show all 42 references

Cited by

See all 33

Metadata

Authors
Castoldi, F., Vacchelli, E., Zitvogel, L., Maiuri, M. C., Pietrocola, F., & Kroemer, G.
Affiliations
  • Université Paris-Sud (FR)
  • Inserm (FR)
  • Karolinska University Hospital (SE)
Corresponding author
Pietrocola, Federico
Venue
OncoImmunology
Published
2018-10
Volume
8
Issue
1
Pages
e1498285-e1498285
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2894877625
Cited by
33
References
42
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 4 · 2021: 7 · 2020: 6 · 2019: 5
FWCI
3.51
Type
journal article
Language
en
Open access
Locations
  • OncoImmunology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Association pour la Recherche sur le Cancer
  • Seerave Foundation
  • E-Rare
  • European Commission
  • Agence Nationale de la Recherche (ANR-17-CE14-0030, ANR-16-RHUS-0008)
  • Fondation Leducq
  • Institut National de la Santé et de la Recherche Médicale
  • Fondation pour la Recherche Médicale
  • Ligue Contre le Cancer
  • Institut Universitaire de France
  • Institut National Du Cancer
  • European Research Area Network on Cardiovascular Diseases
  • Labex Immuno-Oncology
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
autophagy, immunogenic cell death, anthracycline chemotherapy, mitoxantrone, fasting, Beclin-1, ATG4B, chemotherapy toxicity, dendritic cells, tumor immunology, antitumor immunity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy. https://app.cochat.ai/papers/10.1080/2162402x.2018.1498285
The paper
Castoldi, F., Vacchelli, E., Zitvogel, L., Maiuri, M. C., Pietrocola, F., & Kroemer, G. (2019). Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy. OncoImmunology. https://doi.org/10.1080/2162402x.2018.1498285

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.